The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene moieties.
Cucurbit[7]uril Complexation Drives Thermal<i>trans</i>-<i>cis</i>-Azobenzene Isomerization and Enables Colorimetric Amine Detection
作者:Jing Wu、Lyle Isaacs
DOI:10.1002/chem.200901522
日期:2009.11.2
Complexation of yellow diaminoazobenzenes 1 and 3 inside cucurbit[7]uril (CB[7]) results in the formation of purple‐colored CB[7]⋅cis‐1⋅2 H+ and CB[7]⋅cis‐3⋅2 H+ complexes, respectively. The high binding affinity and selectivity displayed by CB[7] toward 1 and 3 pays the >10 kcal mol−1 thermodynamic cost for this isomerization. We investigated the behavior of these complexes as a function of pH and
A Concerted Transfer Hydrogenolysis: 1,3,2-Diazaphospholene-Catalyzed Hydrogenation of NN Bond with Ammonia-Borane
作者:Che Chang Chong、Hajime Hirao、Rei Kinjo
DOI:10.1002/anie.201400099
日期:2014.3.24
1,3,2‐diazaphospholenescatalyzemetal‐free transfer hydrogenation of a NN double bond using ammonia–borane under mild reaction conditions, thus allowing access to various hydrazine derivatives. Kinetic and computational studies revealed that the rate‐determining step involves simultaneous breakage of the BH and NH bonds of ammonia–borane. The reaction is therefore viewed as a concerted type of
Conjugates are provided which comprise a membrane permeable drug linked to a moiety that is not membrane permeable. Attachment of the moiety that is not membrane permeable prevents the drug from crossing cell membranes and entering cells. However, exposure to light either i) breaks the linkage, releasing the drug and allowing it to enter cells; or ii) converts the non-membrane permeable moiety to a membrane permeable form, allowing the entire conjugate to enter the cell, where the drug is released from the conjugate by cleavage. The membrane permeable drugs are thus delivered to cells at locations of interest, e.g. cancer cells in a tumor, in a temporally and spatially controlled manner.
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.